Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | MLYCD | O95822 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426307 | 0.88 | MAPT (0.74) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL31503975 | 0.87 | LMNA (0.78) | MAPTKDM4EMLYCDRAB9ANPC1 | |
| SCHEMBL5431174 | 0.87 | ALDH1A1 (0.65) | MAPTKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL14096043 | 0.87 | MAPT (0.80) | MAPTKDM4ERAB9ANPC1MEN1 | |
| SCHEMBL28579207 | 0.86 | MEN1 (0.66) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL5424498 | 0.86 | KMT2A (0.67) | MAPTKDM4ERAB9ANPC1MEN1 | |
| SCHEMBL7941760 | 0.85 | MLYCD (0.70) | MAPTMLYCDRAB9ANPC1MEN1 | |
| SCHEMBL17148029 | 0.85 | MEN1 (0.78) | MAPTKDM4ERAB9ANPC1MEN1 | |
| SCHEMBL3498895 | 0.84 | LMNA (0.78) | MAPTMLYCDRAB9ANPC1MEN1 | |
| SCHEMBL30776636 | 0.84 | MLYCD (0.68) | MAPTMLYCDRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2010-07-01 | — | — | US | disclosed |
| US-7696231-B2 | Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. | 2005-02-24 | — | — | US | disclosed |
| EP-1439834-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037328-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | PTPRO, PTPRE, PTPRZ1 | MAPT 4427/4885KDM4E 2215/4885MLYCD 2672/4885 |
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | PTPRO, PTPRE, PTPRZ1 | MAPT 4446/4885KDM4E 2146/4885MLYCD 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.